Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.39 |
| ▸ | GABRE | P78334 | 1/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.39 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9704069 | 0.98 | QDPR (0.42) | QDPRGABRPGABRDGABRA1TSHR | |
| Hydrochloric Acid SCHEMBL11074886 | 0.98 | QDPR (0.42) | QDPRGABRPGABRDGABRA1TSHR | |
| SCHEMBL25335980 | 0.88 | TSHR (0.37) | QDPRGABRPGABRDGABRA1TSHR | |
| Formaldehyde SCHEMBL25335355 | 0.85 | TSHR (0.37) | QDPRGABRPGABRDGABRA1TSHR | |
| SCHEMBL1538433 | 0.83 | QDPR (0.43) | QDPR | |
| SCHEMBL9203433 | 0.82 | QDPR (0.42) | QDPR | |
| SCHEMBL11887371 | 0.82 | QDPR (0.42) | QDPR | |
| Hydrochloric Acid SCHEMBL9569043 | 0.82 | QDPR (0.42) | QDPR | |
| Hydrochloric Acid SCHEMBL10875573 | 0.80 | QDPR (0.41) | QDPR | |
| Hydrochloric Acid SCHEMBL14311881 | 0.80 | QDPR (0.41) | QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12201631-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and fragile X syndrome | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-01-21 | — | — | US | claimed |
| US-20230031479-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-02-02 | — | — | US | claimed |
| US-11547706-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and Fragile X syndrome | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-01-10 | — | — | US | claimed |
| US-7199105-B2 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-04-03 | — | — | US | claimed |
| US-20250186429-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-06-12 | — | — | US | disclosed |
| US-12201631-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and fragile X syndrome | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-01-21 | — | — | US | disclosed |
| CN-117777099-A | PARP7 inhibitors and uses thereof | 诺沃斯达药业(上海)有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2023205653-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230031479-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-02-02 | — | — | US | disclosed |
| US-11547706-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and Fragile X syndrome | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2022140555-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-2920149-B1 | 3-AMINOCYCLOALKYL COMPOUNDS AS ROR-GAMMA-T INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2019-03-20 | — | — | EP | disclosed |
| US-4447434-A | ANTIULCER, ANTISECRETORY, OR ANTICHOLINERGIC AGENTS | DR. KARL THOMAE GMBH (DE) | 1984-05-08 | — | — | US | disclosed |
| US-4424226-A | ANTIULCER AGENTS | DR. KARL THOMAE GMBH (DE) | 1984-01-03 | — | — | US | disclosed |
| US-4424225-A | ANTIULCER AGENTS | DR. KARL THOMAE GMBH (DE) | 1984-01-03 | — | — | US | disclosed |
| EP-0086982-A1 | Substituted thienobenzodiazepinones, process for preparing them and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1983-08-31 | — | — | EP | disclosed |
| EP-0085892-A1 | Substituted benzodiazepinones, process for their preparation and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1983-08-17 | — | — | EP | disclosed |
| EP-0085899-A2 | Pyridobenzodiazepinones, process for their preparation and pharmaceutical compositions containing them | Dr. Karl Thomae GmbH (DE) | 1983-08-17 | — | — | EP | disclosed |
| EP-0035924-B1 | BENZOTHIOPYRANO(2,3-C) PYRIDINES AND THEIR ACID ADDITION SALTS, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1983-08-03 | — | — | EP | disclosed |
| EP-0035924-A1 | Benzothiopyrano(2,3-c) pyridines and their acid addition salts, their preparation, their use as medicaments and compositions containing them | ROUSSEL-UCLAF (FR) | 1981-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186429-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | MECP2, GABBR1, GABBR2 | QDPR 3231/4885GABRP 25/4885GABRD 23/4885 |
| US-11547706-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and Fragile X syndrome | MECP2, GABBR1, GABBR2 | QDPR 3231/4885GABRP 25/4885GABRD 23/4885 |
| US-12201631-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and fragile X syndrome | MECP2, GABBR1, GABBR2 | QDPR 3231/4885GABRP 25/4885GABRD 23/4885 |
| US-20230031479-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | MECP2, GABBR1, GABBR2 | QDPR 3231/4885GABRP 25/4885GABRD 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.